Selenoprotein P and Non-alcoholic Fatty Liver Disease

This study has been completed.
Information provided by:
Korea University Identifier:
First received: December 9, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted

The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to steatohepatitis.

Selenoprotein P(SeP) is a secretory protein primarily produced by the liver. Previous studies demonstrated that SeP, a liver-derived secretory protein, causes insulin resistance.

Therefore, the purpose of this study is to determine the different Sep levels between healthy normal group and NAFLD group.

Non-Alcoholic Fatty Liver Disease
Insulin Resistance

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Selenoprotein P and Non-alcoholic Fatty Liver Disease

Resource links provided by NLM:

Further study details as provided by Korea University:

Primary Outcome Measures:
  • Selenoprotein P [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • DXA-measured trunk fat mass [ Designated as safety issue: No ]
  • CT-measured visceral fat area [ Designated as safety issue: No ]

Enrollment: 120
Study Start Date: September 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Control Group


Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers for visiting routine medical check in our clinic

Inclusion Criteria:

  • Healthy volunteers for visiting routine medical check in our clinic

Exclusion Criteria:

  • History of cardiovascular disease(myocardial infarction, unstable angina, or cardiovascular revascularization)
  • Diabetes
  • Hypertension
  • Malignancy
  • Severe renal or hepatic disease
  • Subjects taking medications that might affect body weight or body composition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01257685

Korea, Republic of
Hae Yoon Choi
Seoul, Korea, Republic of, 152-703
Sponsors and Collaborators
Korea University
Study Director: Kyung Mook Choi, MD.PhD Korea University
  More Information

Responsible Party: Kyung Mook Choi, Korea university Identifier: NCT01257685     History of Changes
Other Study ID Numbers: SEPP1(NAFLD) 
Study First Received: December 9, 2010
Last Updated: December 9, 2010
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Fatty Liver
Insulin Resistance
Liver Diseases
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Glucose Metabolism Disorders
Metabolic Diseases processed this record on May 23, 2016